Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these substances boost insulin release and red

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising mechanisms for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class